Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients

OBJECTIVES: A phase I pretargeted radioimmunotherapy trial (EudractCT 200800603096) was designed in patients with metastatic lung cancer expressing carcinoembryonic antigen (CEA) to optimize bispecific antibody and labeled peptide doses, as well as the delay between their injections. METHODS: Three...

Descripción completa

Detalles Bibliográficos
Autores principales: Bodet-Milin, Caroline, Ferrer, Ludovic, Rauscher, Aurore, Masson, Damien, Rbah-Vidal, Latifa, Faivre-Chauvet, Alain, Cerato, Evelyne, Rousseau, Caroline, Hureaux, José, Couturier, Olivier, Salaün, Pierre-Yves, Goldenberg, David M., Sharkey, Robert M., Kraeber-Bodéré, Françoise, Barbet, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661432/
https://www.ncbi.nlm.nih.gov/pubmed/26640780
http://dx.doi.org/10.3389/fmed.2015.00084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661432/
https://www.ncbi.nlm.nih.gov/pubmed/26640780
http://dx.doi.org/10.3389/fmed.2015.00084

Ejemplares similares